Men face double dementia risk if they have a hidden genetic mutation
That's according to an Australian study led by Monash and Curtin Universities, which analyzed the medical data of thousands of Australians and Americans.
Men who had a certain variant in the haemochromatosis (HFE) gene — which regulates iron levels in the body — were found to be at a higher risk of dementia, the researchers found.
Previously healthy men over age 70 who have two copies of the variant, which is known as H63D, are at least twice — or up to four times — as likely to develop dementia.
Having just one copy did not appear to elevate the risk.
One in 36 men carry two copies of the mutation; one in three have just a single copy.
"It is only men who have two copies of the variant that are at risk," study co-author Professor John Olynyk from the Curtin Medical School told Fox News Digital. "Women are not affected by the abnormality – we do not know why that is at the current point in time."
The study, which was published in the journal Neurology, used data from the ASPirin in Reducing Events in the Elderly (ASPREE) trial, which gathered health and aging data for 19,114 healthy older adults.
Those who have the genetic variant can't change it, but it's possible that the "brain pathways" it affects could be treated, Olynyk noted.
"The HFE gene is routinely tested for in most Western countries … when assessing people for haemochromatosis, a disorder that causes the body to absorb too much iron," the doctor said. "Our findings suggest that perhaps this testing could be offered to men more broadly."
Despite the fact that the HFE gene is responsible for controlling iron levels, the team found no direct link between iron and dementia risk.
"Our findings suggest that perhaps this testing could be offered to men more broadly."
"This points to other mechanisms at play, possibly involving the increased risk of brain injury from inflammation and cell damage in the body," Olynyk added.
More research is needed to determine why the heightened risk wasn't seen in women.
"Understanding why men with the double H63D variant are at higher risk could pave the way for more personalized approaches to prevention and treatment," added co-author Professor Paul Lacaze from Monash University in a press release.
The main limitation of the study, according to Olynyk, was that the study population was largely composed of Australians.
"Whether other populations exhibit the same effects is unclear," he told Fox News Digital. "Our work should be repeated in different countries to assess this."
"Further research will be undertaken to try and determine the likely mechanism by which this anomaly causes dementia and what more we can do to reduce the impact of it."
Beyond this specific mutation, many other genetic and environmental factors can contribute to dementia risk, Olynyk noted.
"While genetic risk factors cannot be changed, the mechanisms by which these genetic abnormalities and environmental factors cause disease may well be modifiable to some extent, through adopting a healthy lifestyle and being proactive about maintaining an overall good state of health," he said.
To reduce risk, the researchers recommend adopting a healthy lifestyle that includes exercising regularly, eating a nutritious diet, minimizing alcohol intake, remaining mentally active, and seeing a doctor to address any medical problem known to increase the likelihood of dementia.
For more Health articles, visit www.foxnews.com/health
The University of Melbourne, The Royal Children's Hospital, Murdoch Children's Research Institute and Fiona Stanley Hospital also contributed to the study.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
26 minutes ago
- Medscape
IDSA Issues Updated Guidelines on Complicated UTIs
The Infectious Diseases Society of America's (IDSA's) updated guidelines for management and treatment of complicated urinary tract infections (UTIs) include a streamlined classification and new advice on antibiotics. The guidelines, published on the IDSA website, specifically address complicated UTIs (cUTIs) and expand recommendations for men, both of which had not been emphasized in the existing IDSA guidelines on UTIs (last updated in 2010). 'IDSA's new guidelines are intended to support clinicians from many different disciplines with the latest scientific knowledge on how to manage complicated UTIs,' said lead author Barbara Trautner, MD, co-chief of the Infectious Diseases Division at Washington University in St. Louis, in an IDSA press release announcing the guidelines. Since 2010, many antimicrobials have emerged for cUTIs, which are now defined as an infection beyond the bladder in women or men, including pyelonephritis, febrile or bacteremic UTIs, catheter-associated UTIs, and prostatitis. Although prostatitis is now part of the definition of cUTIs, management is not specifically addressed in the new guidelines, the authors wrote. Uncomplicated UTIs are defined in the new guidelines as infections confined to the bladder in afebrile women or men. 'The guidelines provide a welcome update and clarity to treating a commonly encountered infection,' said Neil Skolnik, MD, professor of family and community medicine at the Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, in an interview. 'This is one of the few guidelines that I have seen where I don't actually think there will be barriers to implementation,' he said. Go Early, Then Easy, on Oral Antibiotics Notably, the recommendations suggest algorithms for the use of antibiotics, including a four-step process to assess illness severity, resistance risk factors, patient-specific considerations, and, for septic patients, consideration of local antibiotic susceptibility (the antibiogram). For patients who started on parenteral therapy but are improving and able to take oral medication, switching to oral antibiotics for the remainder of the treatment period is recommended if an effective oral option is available, according to the guidelines. An earlier switch to oral treatment would reduce costs and the risk for catheter-related adverse events, the authors noted. The guidelines also recommend a relatively short duration of antibiotic use for patients with uncomplicated UTIs who are improving: either 5-7 days of a fluoroquinolone or 7 days of a non-fluoroquinolone antibiotic. Simple Updates to Treat Complicated Cases 'I was thrilled to see the updated guidance from IDSA, as they represent the most important and credible organization that gives guideline-based recommendations on infectious diseases, of which UTI is an important one,' Skolnik said. 'I was not surprised that pyelonephritis was reclassified from uncomplicated to complicated UTI,' Skolnik told Medscape Medical News . 'In fact, I was surprised that it was considered uncomplicated in the previous guidelines,' he noted. An important point about the updated guidelines is the emphasis on individualized treatment of complicated UTIs, recognizing that treatment depends on the severity of illness, risk factors for having resistant uropathogens, patient-specific considerations, and the local antibiogram, Skolnik said. For example, the recommendation for patients with sepsis resulting from a UTI 'places a higher value on providing early, appropriate empiric antibiotic therapy to prevent mortality while deferring stewardship considerations to definitive therapy,' Skolnik noted. 'For patients who are less severely ill, antibiotic stewardship becomes more important,' he said. Skolnik said he was pleased to see the inclusion of 'good old trimethoprim-sulfamethoxazole' as a preferred oral agent for patients with complicated UTIs without sepsis who do not require intravenous therapy. 'I was also happy to see that fluoroquinolones are still first line in this population, and amoxicillin-clavulanate or oral cephalosporins still are recommended as reliable alternative agents,' Skolnik told Medscape Medical News . These antibiotics are widely used in primary care, he added. However, for complicated UTIs, 'it is particularly helpful to have duration of antibiotic treatment clarified as 7 days total duration, rather than a longer course, as many clinicians currently treat for 10-14 days,' he noted. The new guidelines were developed by a panel of experts, including physicians and pharmacists, with review by multiple medical organizations, including the Society of Infectious Diseases Pharmacists, American Academy of Family Physicians, Society of Hospital Medicine, American Urological Association, American Society for Microbiology, Society for Academic Emergency Medicine, Association of Medical Microbiology and Infectious Disease Canada, and European Society of Clinical Microbiology and Infectious Diseases.
Medscape
26 minutes ago
- Medscape
New Glioma Guidelines Incorporate WHO Reclassification
Newly updated guidelines from the American Society for Radiation Oncology (ASTRO) capture the World Health Organization (WHO)'s 2021 reclassification of glioblastoma as grade 4 adult-type diffuse gliomas. The new ASTRO guidelines and the WHO reclassification incorporate newly discovered molecular markers with histologic findings, which allow clinicians to more precisely diagnose and treat these tumors. The term glioblastoma now refers only to IDH wild-type gliomas, which grow more quickly and are more aggressive that IDH mutant gliomas. The guidelines also incorporate the use of newer imaging techniques. The ASTRO guidelines were last updated in 2016. According to guideline co-author Steve E. Braunstein, MD, PhD, the treatment of older and/or medically frail patients was one of the topics the guidelines task force spent the most time discussing. Despite 'dozens and dozens of high-quality clinical trials that have been done, there are still areas where we don't have a clear consensus or a clear, high-level evidence-based approach for treating those patients…who are somewhat older or more medically frail,' Braunstein told Medscape Medical News in an interview. The task force observed that even assessing two or three factors like performance status and age doesn't really capture the patient and how they're going to best respond to therapy. The guidelines offer suggested dose-fractionation regimens for radiation therapy (RT) guided by the patient's age and functional status with shorter courses conditionally recommended for older patients and those with indications of frailty. Supportive care is conditionally recommended in lieu of chemoradiation for patients with markers of severe frailty, who are often at an increased risk for complications from intensive treatments. However, for both groups — older/more frail and severely frail patients — the appropriate treatment approach should flow from a multidisciplinary, patient-centered discussion. 'We recognize that we need to do more to understand these patients in a deeper way in order to bestow upon them appropriate personalized recommendations,' said Braunstein, who is also vice chair of radiation oncology at the University of California San Francisco. Reirradiation Conditionally Recommended for WHO Grade 4 Diffuse Glioma The task force conditionally recommended reirradiation for WHO grade 4 diffuse glioma recurrence for selected adult patients with good functional status, following a multidisciplinary, patient-centered discussion. This discussion would address indications and techniques for reirradiation, specifically diagnostic and treatment considerations and systemic therapy in the reirradiation setting. At least one expert interviewed by Medscape Medical News questioned this recommendation. 'For recurrent glioblastomas, they suggest that reirradiation is an option…the endorsement of that approach is fairly significant,' said Patrick Y. Wen, MD, is director of the Center for Neuro-Oncology at Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School in Boston. 'In fact, we actually don't know if reirradiation works.' He added that the guidelines could be more balanced in outlining the limitations of reirradiation. 'We all do it because there's nothing else to do, but that doesn't mean it's a great choice.' Wen, who was not involved in the development of the guidelines, said there has only been one randomized trial, which compared Avastin [bevacizumab], which is standard of care, with bevacizumab and radiation. Although patients who received the combination had decreased progression-free survival, there was no improvement in overall survival. Wen noted that there has only been one randomized trial, which compared Avastin [bevacizumab], which is standard of care, with bevacizumab and radiation. Although patients who received the combination had improved progression-free survival, there was no improvement in overall survival. 'So you could interpret that as the only randomized study out there…showing no survival benefit.' There is a trial being conducted by the European Organisation for Research and Treatment of Cancer, the LEGATO trial, that is currently evaluating whether reirradiation and lomustine improves survival compared with standard lomustine chemotherapy alone. The data that do exist supporting the use of reirradiation come entirely from retrospective studies, he added. 'There's huge selection bias with retrospective data because the patients, who you would radiate are the ones that have small tumors and that are probably in decent shape, so they're going to do better.' In addition to making the conditional recommendation for reirradiation, the task force acknowledged care disparities for patients from diverse backgrounds. More Studies Needed to Examine Barriers to Access, Clinical Trial Enrollment 'There are great disparities in the care of patients, who are coming from different backgrounds,' said Braunstein. 'Those are a function of things that could include age, geography, insurance status, ethnic background, and race, among others. We really want to ensure that we're giving every patient with this terrible diagnosis, the opportunity to have the best care possible.' As part of the discussion, the task force reviewed the literature on health disparities and adult high-grade glioma, calling to attention the need for more studies that examine barriers to access and the need to increase clinical trial enrollment for underserved populations. Other key recommendations for patients with grade 4 adult-type diffuse gliomas include: Fractionated RT for those who have undergone biopsy or resection; optimal timing and fractionation schedules for adjuvant RT are included. Concurrent temozolomide chemotherapy and RT are recommended following biopsy or resection. Alternating electric field therapy — a cancer treatment using low-intensity, intermediate frequency electrical fields — is conditionally recommended following RT for those with tumors in the upper regions of the brain (ie, supratentorial disease). Braunstein reported relationships with Elekta GT Medical Tech (consultant) and Icotec Medical (honoraria, travel expenses).
WIRED
28 minutes ago
- WIRED
Einstein Showed That Time Is Relative. But … Why Is It?
Jul 18, 2025 7:00 AM The mind-bending concept of time dilation results from a seemingly harmless assumption—that the speed of light is the same for all observers. Video:So, you're driving a car at half the speed of light. (Both hands on the wheel, please.) You turn on the headlights. How fast would you see this light traveling? What about a person standing by the road? Would they see the light beam moving at 1.5 times the speed of light? But that's impossible, right? Nothing is faster than light. Yes, it seems tricky. The problem is, our ideas about the world are based on our experiences, and we don't have much experience going that fast. I mean, the speed of light is 3 x 108 meters per second, a number we represent with the letter c. That's 670 million miles per hour, friend, and things start to get weird at extreme speeds. Illustration: Rhett Allain It turns out that both the driver and the person on the road would measure the light as traveling at the same speed, c. The motion of the light source (the car) and the relative motion of the observers make no difference. Albert Einstein predicted this in 1905, and it's one of the two main postulates behind his theory of special relativity. Oh, it doesn't sound so 'special' to you? Well, what he then showed is that if the speed of light is a universal constant, then time is relative . The faster you move through space, the slower you move through time. The clock on a hyper-speed spaceship would literally tick slower, and if you were in that ship, you would age more slowly than your friends back home. That's called time dilation. A Commonsense Example The idea that everyone sees light traveling at the same speed seems like common sense. But let's look at a more familiar situation, and you'll see that it's not how things usually work. Say you're driving at 10 meters per second, and someone in the car takes a tennis ball and throws it forward with a speed of 20 m/s. A bystander who happens to have a radar gun measures the speed of the ball. What reading do they get ? Illustration: Rhett Allain Nope, NOT 20 m/s. To them the ball is moving at 30 m/s (i.e., 10 + 20). So much for common sense. The difference arises from the fact that they are measuring from different 'reference frames,' one moving, the other stationary. It's all good, though; everyone agrees on the outcome. If the ball hits the person, the miscreants and the bystander would calculate the same time of impact. Yes, the people in the car see the ball moving at a slower speed, but they also see the bystander moving toward them (from their perspective), so it works out the same in the end. This is the other main postulate of special relativity: The physics are the same for all reference frames—or to be specific, for all 'inertial,' or non-accelerating, frames. Observers can be moving at different velocities, but those velocities have to be constant. Anyway, now maybe you can see why it's actually quite bizarre that the speed of light is the same for all observers, regardless of their motion. Waves in an Empty Sea How did Einstein get this crazy idea ? I'm going to show you two reasons. The first is that light is an electromagnetic wave. Physicists had long known that light behaved like a wave. But waves need a medium to 'wave' in. Ocean waves require water; sound waves require air. Remove the medium and there is no wave. But then, what medium was sunlight passing through as it traveled through space? In the 1800s, many physicists believed there must be a medium in space, and they called it the luminiferous aether because that's fun to say. In 1887, Albert Michelson and Edward Morley devised a clever experiment to detect this aether. They built a device called an interferometer, which split a beam of light in half and sent the halves along two paths of equal length, bouncing off mirrors, and merging again at a detector, like this: Illustration: Rhett Allain Obviously they didn't have a laser, but they had a similar light source. Now, if the Earth was moving through an aether as it circled the sun, that aether would change the speed of light, depending on whether the light was moving in the direction of Earth's motion or at a right angle to that motion. And here's the genius part: They didn't have to actually measure the speed of light, they only had to see if the two beams arrived at the detector at the same time. If there was any change in speed, the beams would be out of sync and would cancel each other when recombined. That interference would show up as a dark spot on the detector. If they moved at exactly the same speed, the sinusoidal waves would align and you'd see a bright spot. They ran this experiment at all different times of year to get different angles with respect to the sun, but the result was always the same. There was no change in speed—which meant, sadly, that people had to stop saying 'luminiferous aether.' Evidently, light waves could travel through a vacuum! Maxwell's Equations and Reference Frames The reason for this, as proven by Heinrich Hertz, is that light is an electromagnetic wave—an oscillation of electric and magnetic fields perpendicular to each other. The changing electric field creates a magnetic field, and the changing magnetic field creates an electric field, and this endless cycle makes light self-propagating. It can travel through empty space because it's two waves in one. Now for the rough part (mathematically). We know the relationship between the electric and magnetic fields—it's described in Maxwell's famous four equations. If you use some math stuff (full details here), it's possible to write the following equations for the electric field (E) and the magnetic field (B). (If all these Greek symbols are Greek to you, just skip over this.) All you need to know is that, together, these equations describe an electromagnetic wave. But wait! That's not all. If we plug in the values of μ 0 and ε 0 —the fundamental magnetic and electric constants, respectively—you get a wave speed (v for velocity) that is exactly the speed of light: Einstein used this to postulate that the speed of light was the same for all observers. How? Well, since we accepted that any one inertial reference frame is as valid as another, Maxwell's equations must work in both. That means the speed of light is the same in both reference frames—even if they're in motion relative to one another. UNLIKE the tennis ball scenario above! Time Dilation Finally, imagine we build a clock to measure time. Not one of your grandfather's clocks with a swinging pendulum, which would be a problem in zero gravity. Our clock is cooler than that. Basically we get two parallel mirrors and bounce a pulse of light back and forth between them. Illustration: Rhett Allain If we know the distance between the mirrors (s) and the speed of the light (we do, it's c), then we can calculate the time for one tick. Now assume our clock is in a spaceship with a big window, like in the movies. This spaceship is moving with a constant velocity that is half the speed of light (c/2) with respect to some nearby planet. Someone on that planet uses a telescope to look through the spaceship window and peek at the light clock. Here's what that planet person would see: Illustration: Rhett Allain Notice that since the spaceship is moving, the light has to travel at an angle in order to hit the other spot on the opposite mirror. If we continued this, it would be a series of zigzags. Take a minute to think about that. It's like if you were riding in a bus and tossed a ball straight up and then caught it without moving your hand. In your reference frame, the ball just moves straight up and down. But to that guy on the street, the ball would trace out an arc, moving up and down but also forward. In our light clock, since the light has to travel at an angle to hit the correct spot, it travels a farther distance . Oh, but that light still travels at the speed of light, so it takes more time to reach the other mirror. And if the spaceship is moving at a speed of c/2, that would be a lot more time. Result? As seen from the person on the planet, the spaceship clock ticks slower. There you have it: time dilation. Does this mean that time goes slower for the people on the spaceship? Nope. In their reference frame the light just bounces up and down and time is normal. Yes, it seems very weird, but it's not. It only seems weird because we never travel anywhere near the speed of light. In fact, time slows down in any moving vehicle—even when you get in your car and drive to work—but at normal speeds the effect is so tiny that it's imperceptible.
